Compare Cytokinetics Inc (CYTK) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Thomson Reuters Corp — how do they compare? Cytokinetics Inc trades at $81.99 (market cap $11.16B), while Thomson Reuters Corp trades at $94.22 (market cap $40.96B). The key difference: Thomson Reuters Corp is far larger — about 3.7× Cytokinetics Inc's market cap, and Thomson Reuters Corp pays a 2.78% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | TRI | |
|---|---|---|
Market Cap | $11.16B | $40.96B |
Sector | Technology | Industrials |
52-Week High | $87.26 | $211.14 |
52-Week Low | $33.23 | $76.55 |
Enterprise Value | $11.63B | $42.92B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Thomson Reuters (TRI) trades at $94.29, up 5.18% today, showing strong momentum near resistance at $95. The stock maintains solid fundamentals with a 19.93% net margin and has beaten earnings estimates in two of the last three quarters. Recent developments include a joint venture with KKR and continued AI integration, positioning the company for growth in legal and professional markets.
The outlook is positive with a consensus price target of $129.96 implying 38% upside, supported by bullish analyst ratings (52% Buy). Key risks include execution of AI strategies and potential revenue pressures from market shifts. Institutional confidence remains high given stable cash flows and strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
